2022
Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
Garot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100515. PMID: 39132534, PMCID: PMC11308104, DOI: 10.1016/j.jscai.2022.100515.Peer-Reviewed Original ResearchDrug-eluting stentsDurable polymer everolimus-eluting stentsEverolimus-eluting stentsIII trialsLesion failureClinical outcomesMyocardial infarctionMajor adverse cardiac eventsVessel-related myocardial infarctionBiodegradable polymer drug-eluting stentsAdverse cardiac eventsOutcomes of patientsTarget lesion failureTarget lesion revascularizationLesion revascularizationCardiac eventsPatient characteristicsCardiac deathDES groupProcedural successStent thrombosisSubgroup analysisPatient outcomesNonsignificant trendEnrollment locationTCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial
Kelbæk H, Lansky A, Xu B, Baumbach A, van Royen N, Knaapen P, Johnson T, Smits P, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Wijns W. TCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial. Journal Of The American College Of Cardiology 2022, 80: b66. DOI: 10.1016/j.jacc.2022.08.193.Peer-Reviewed Original ResearchDepression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience)
Murugiah K, Chen L, Dreyer RP, Bouras G, Safdar B, Lu Y, Spatz ES, Gupta A, Khera R, Ng VG, Bueno H, Tweet MS, Spertus JA, Hayes SN, Lansky A, Krumholz HM. Depression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience). The American Journal Of Cardiology 2022, 173: 33-38. PMID: 35365290, PMCID: PMC9133198, DOI: 10.1016/j.amjcard.2022.03.005.Peer-Reviewed Original ResearchConceptsSpontaneous coronary artery dissectionPatient Health Questionnaire-9Coronary artery dissectionPSS-14 scoreArtery dissectionBaseline PHQ-9 scoreAcute myocardial infarction patientsCardiovascular risk factorsPHQ-9 scoresAcute myocardial infarctionMyocardial infarction patientsYears of agePerceived Stress Scale scoresStress Scale scoresLinear mixed-effects analysisSCAD casesVIRGO StudyQuestionnaire-9Infarction patientsMixed-effects analysisMyocardial infarctionSubgroup analysisRisk factorsRoutine screeningClinical acuity
2021
TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial
Hussain Y, Wijns W, Xu B, Kelbæk H, Knaapen P, Zheng M, Slagboom T, Johnson T, Smits P, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schachinger V, Baumbach A, Lansky A. TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2021, 78: b200. DOI: 10.1016/j.jacc.2021.09.1342.Peer-Reviewed Original Research
2018
TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial
Lansky A, Wijns W, Xu B, Kelbaek H, van Royen N, Zheng M, Artus-Jacenko L, Knaapen P, Slagboom T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Bruder O, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Johnson T, Thiele H, Baumbach A. TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2018, 72: b249-b250. DOI: 10.1016/j.jacc.2018.08.1826.Peer-Reviewed Original Research
2012
Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
Meier P, Indermuehle A, Pitt B, Traupe T, de Marchi SF, Crake T, Knapp G, Lansky AJ, Seiler C. Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis. BMC Medicine 2012, 10: 62. PMID: 22720974, PMCID: PMC3386894, DOI: 10.1186/1741-7015-10-62.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary collateral circulationCoronary artery diseaseRisk ratioCoronary interventionCollateral circulationGood collateralizationCoronary collateralsStable coronary artery diseaseGood coronary collateralizationSummary risk ratiosSubgroup of patientsAcute myocardial infarctionRisk of restenosisIntracoronary pressure measurementsRandom-effects modelPoor collateralsAngiographic restenosisPrimary endpointArtery diseaseCoronary collateralizationRisk stratificationResultsA totalMyocardial infarctionSubgroup analysisClinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, Stone GW. Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2012, 59: 1752-1759. PMID: 22575312, DOI: 10.1016/j.jacc.2011.12.042.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionHospital stent thrombosisPrimary percutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialStent thrombosisMajor bleedingClinical outcomesUnfractionated heparinMyocardial infarctionST eventsPrimary PCIIIb/IIIa inhibitorsProbable stent thrombosisAcademic Research ConsortiumElevation myocardial infarctionPercutaneous coronary interventionSTEMI patientsCoronary interventionHospital phaseBetter prognosisMultivariable analysisReperfusion resultsSubgroup analysisMost deaths
2007
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, investigators F. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. The Lancet 2007, 369: 907-919. PMID: 17368152, DOI: 10.1016/s0140-6736(07)60450-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyDrug Therapy, CombinationEnoxaparinFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial IschemiaPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsPercutaneous coronary interventionAcute coronary syndromeNet clinical outcomeHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialCoronary interventionClinical outcomesMajor bleedingCoronary syndromeAcute CatheterizationStrategy trialDirect thrombin inhibitor bivalirudinAdverse ischemic eventsMajor haemorrhagic complicationsComparable clinical outcomesThrombin inhibitor bivalirudinHaemorrhagic complicationsIschemic eventsUnfractionated heparinSubgroup analysisProportion of individualsBivalirudinBleeding
2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial
Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial. American Heart Journal 2006, 151: 1032.e1-1032.e7. PMID: 16644331, DOI: 10.1016/j.ahj.2006.02.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationFemaleHemorrhageHeparinHirudinsHumansMaleMulticenter Studies as TopicMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk AssessmentSex FactorsConceptsPercutaneous coronary interventionIschemic end pointsComposite ischemic end pointsContemporary percutaneous coronary interventionGpIIb-IIIa blockadeEnd pointMajor bleedingCoronary interventionMyocardial infarctionSubgroup analysisProvisional glycoprotein IIb/IIIa blockadeGlycoprotein IIb/IIIa blockadeAccess site bleedingInherent bleeding riskPCI Linking AngiomaxCongestive heart failureSex-based subgroup analysisPrior revascularizationUrgent revascularizationBleeding riskMinor bleedingMore diabetesSite bleedingHeart failurePoor outcome